Abstract: Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Abstract: A previously uncharacterized gene and gene product are disclosed herein that increase blood glucose clearance independent of insulin. Also described is a methodology for enriching for mRNAs transcribing excreted and membrane bound proteins as well as a non-human animal expressing a labeled SEC61b protein.

Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are differentiation methods for producing SC-? cells, as well as methods for screening stem cell-derived cells to measure gene expression. Also disclosed herein are SC-EC cells.

Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods, differentiation protocols and compositions useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are compositions and methods for the generation of insulin positive ? cells, for example by exposing Pdx+ pancreatic progenitor cells to one or more compounds, and compositions and kits comprising isolated populations of insulin positive cells.

Abstract: Disclosed herein are methods for generating SC-? cells, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods for generating SC-? cells, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.